Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Insmed execs sold millions in company stock, but analysts maintain a "Moderate Buy" rating.

flag Insmed Incorporated's executives, including CFO Sara Bonstein, COO Roger Adsett, and CEO William Lewis, have recently sold significant amounts of company stock, totaling millions of dollars. flag Despite these sales, large investors have increased their stakes, and analysts have maintained a "Moderate Buy" consensus with a target price of $85. flag Insmed, a biopharmaceutical company, develops treatments for rare diseases, with its first product, ARIKAYCE®, approved for treating lung disease.

6 Articles

Further Reading